July 29, 2022 10:30 AM EDT
R&D
Pharma

Bris­tol My­er­s' com­bo hits a road­block in PhI­II kid­ney test as the search to ri­val Keytru­da con­tin­ues

Tyler Patchen

News Reporter

Bris­tol My­ers Squibb has hit a snag in its Phase III tri­al in­ves­ti­gat­ing the com­pa­ny’s Op­di­vo and Yer­voy com­bo in re­nal cell car­ci­no­ma, or RCC …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times